6,655 press releases indexed under healthcare.
PDA announced today that senior leaders from the FDA's centers for drugs, biologics and veterinary medicine as well as the Office of Inspections and Investigations will participate in the plenary on Monday, Sept. 14, as part of the 2026 PDA/FDA Joint Regulatory Conference in Washington, D....
VERAXA Biotech and Secarna Pharmaceuticals have reported an initial in vitro proof of concept for an antibody oligonucleotide conjugate (“AOC”) developed through their research alliance. The AOC candidate demonstrated greater potency than the equivalent unconjugated oligonucleotide in early testing, providing a first experimental validation of the collaboration. AOCs are an emerging class of antibody-guided therapies designed to use an antibody to deliver therapeutic oligonucleotides selectively to disease-relevant cells. VERAXA contributes antibody conjugation expertise and proprietary click chemistry, allowing it to participate in AOCs without shifting its core oncology strategy. The collaboration adds to VERAXA’s growing partnering track record, which also includes its bispecific ADC di
Jury finds Parse willfully infringed Scale Biosciences' patents and rejects Parse's invalidity challenge PLEASANTON, Calif., Aug. 28, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today...
Researchers are developing new regenerative approaches, including stem cells, 3D-printed scaffolds and smart biomaterials designed to help the body repair damaged tissue. Focused on smart biomaterials, Regentis is advancing a hydrogel-based approach through GelrinC, a cell-free, off-the-shelf implant designed to support the regeneration of damaged knee cartilage. With encouraging clinical results, European approval and an ongoing U.S. pivotal trial, GelrinC is advancing toward a potential new approach to cartilage repair. LOS ANGELES, CA - August 28, 2026 ( NEWMEDIAWIRE ) - Regenerative medicine is increasingly focused on a simple but ambitious goal: rather than simply treating damaged tissue, can medicine help the body rebuild it? One company pursuing a regenerative approach is Regentis B
OLDWICK, N.J., August 28, 2026--AM Best has affirmed the Long-Term Issuer Credit Rating (Long-Term ICR) of "a-" (Excellent) and the Long and Short-Term Issue Credit Ratings (Long-Term IR; Short-Term IR) of UnitedHealth Group Incorporated (UnitedHealth Group) (Minnetonka, MN) [NYSE: UNH]. Concurrently AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term ICRs of "a+" (Excellent) of the health and dental insurance subsidiaries of UnitedHealth Group, collective
LINCOLN, Neb., Aug. 28, 2026 /PRNewswire/ -- The Dr. Steven Shannon Scholarship for Medical Students is accepting applications from undergraduate students across the United States who are preparing for careers in medicine and related healthcare fields. The one-time scholarship opportunity...
FDA found no factors that could explain the cause of the outbreak in ByHeart facilities FDA responded with no further questions on ByHeart's investigation and Action Plan ByHeart introduces new C. botulinum testing protocols 1000x more sensitive than the standard industry test methodology...
Experienced medical device executive to lead the company through its next phase of clinical, regulatory and strategic development CINCINNATI, Aug. 28, 2026 /PRNewswire/ -- Sense Neuro Diagnostics, a medical technology company developing a novel, non-invasive platform designed to rapidly...
(PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / August 28, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Fractyl Health, Inc. (NASDAQ:GUTS) securities. If you suffered a loss on your Fractyl Health, Inc. investment and would like to explore a potential recovery under the federal securities laws, Learn about Fractyl Health, Inc. Class Action or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak to our team of experienced shareholder advocates. THE LAWSUIT: A class action securities lawsuit was filed ..
Chicago's leading professional dancers return to The Rhapsody Theater stage for three unforgettable performances benefiting the Chicago Dance Health Fund CHICAGO, Aug. 28, 2026 /PRNewswire-PRWeb/ -- The C5 Artists Foundation, a non-profit organization established to support the Chicago...
(PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / August 28, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Hims & Hers Health, Inc. ("Hims" or "the Company") (NYSE:HIMS). Investors who purchased Hims securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/cases/hims-hers-health-inc-hims-class_action_lawsuit. Hims Investigation Details On July 29, 2026, the Federal Trade Commission ("FTC") filed a lawsuit against Hims, accusing it of sharing customers' medical information with third-party advertisers. The FTC's criminal complaint accuses Hims of "deceptive and unlawful privacy practices," including sharing sensitive details about patient ..
World-first procedure marks a significant advancement in the surgical treatment of complex pelvic trauma and underscores the power of academic medicine to bring innovations from development to the operating room. TAMPA, Fla., Aug. 28, 2026 /PRNewswire/ -- Tampa General Hospital and...